

Applicant Last Name:				
Project Title:				
Date of Submission:				
Section 1: Contact Information				
Provide contact information for the principal investigator (PI) of this application. If the PI has designated a representative to submit the proposal on their behalf, please enter the designee's contact information as well.				
1. Project Title:				
<ol> <li>Is this a resubmission of a proposal for a project for which support was previously sought under Catalyze?          Yes         No     </li> </ol>				
3. Principal Investigator (Last Name, First Name):				
4. Organization:				
5. Title:				
6. Department (or Discipline):				
7. Street Address:				
8. City:				
9. State:				
10. Zip code:				
11. PI email address:				
12. PI telephone number:				
13. Name and contact information for corresponding organizational representative, if not the PI:				
14. How did you learn about Catalyze? (Select all that apply):				
NHLBI Catalyze website Scientific conference or news				
NIH Translational Program(s) (e.g., article				
REACH, NCAI, SMARTT, CADET II)  Catalyze event  NIH Program Officer  Other (Please specify):				
My institution/department				

1

Confidential

Investigator: \_\_\_\_\_



## **Section 2: PI Demographic Profile**

Your responses to the following questions allow the Catalyze Coordinating Center to better understand the demographic profile of investigators interested in Catalyze award programs. Your responses to these questions have no influence on proposal selection and will not be shared with reviewers.

15. Position or title:
16. Terminal Degree:
17. Year of Terminal Degree (or Expected Completion Year):
18. Gender: Do you describe yourself as a man, a woman, or in some other way?  Man Mon-binary Prefer not to say
19. Race: What is your race? Please select all that apply
American Indian or Alaska Native  Asian  Black or African American  Native Hawaiian or Other Pacific Islander  White  Other  Prefer not to say
20. Ethnicity: Do you describe yourself as Hispanic or Latino?
<ul> <li>Hispanic or Latino (A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race)</li> <li>Not Hispanic or Latino</li> <li>Prefer not to say</li> </ul>
21. Disability Status: Are you disabled?
☐ Disabled ☐ Not disabled ☐ Prefer not to say
22. Has your professional experience to-date been characterized by any of the following? Select all that apply:
<ul> <li>Been granted a copyright, patent, or trademark</li> <li>Licensed your technology to another party</li> <li>Applied for funding from a translational research, proof-of-concept, or commercialization support program—other than Catalyze</li> <li>Received funding from a translational research, proof-of-concept, or commercialization support program—other than Catalyze</li> <li>Founded a start-up company</li> </ul>
support program—other than Catalyze

Confidential

2

Investigator: \_\_\_\_\_



rovide the following information about the project for which Catalyze assistance is sought.				
app Ple- Ple- doc Ple-	Preclinical Studies (Pharmtox/non-GLP/GLP Studies ase describe (50-word limit):  Chemistry Manufacturing and Controls Work ase describe (50-word limit):  Preclinical Catalyze Coordinating Center Assistance cumentation, gap analysis)  ase describe (50-word limit):	es) e (regulatory guidance and		
	nat is the specific technology or product (50-word li			
27. Wh	nat is the indication (50-word limit)?			
	he project is for a therapeutic, what is the target (echanism of Action) for the product (50-word limit)	• • • • • • • • • • • • • • • • • • • •		
29. In t	two or three sentences, what is the technical goal c	of the project (50-word limit)?		

3

Confidential

Investigator: \_\_\_\_\_



30. Indicate the status of intellectual property protection for this technology
<ul> <li>No invention disclosure filed with technology transfer office (or equivalent)</li> <li>Invention disclosure filed with TTO (or equivalent)</li> <li>A patent application has been submitted</li> <li>A trademark has been registered</li> <li>A copyright has been granted</li> </ul>
31. Do you have efficacy data in a relevant animal model by the route of administration to be used in the clinic? Please describe relevant efficacy data in the Project Description below.
Yes No Not Applicable Other (please specify)
32. For device and diagnostics, have you confirmed conceptualization and proof of concept via prototyping of all or part of the conceived product with supporting data (i.e., animal or known-sample studies) and documentation? Has a Design History File been created?
Yes No Not Applicable Other (please specify)
33. <b>Project Description</b> . In 1,000 words or less, please provide an overall description of your project. Include the project purpose or objective, therapeutic relevance to the NHLBI mission, a description of preliminary studies, a concise description of the studies you are proposing, the unmet market need or innovation to potentially change standard of care, and commercialization path.
34. Explain why support for this project is sought from NHLBI and the Catalyze program as opposed to private sector or other sources of support.

## **Section 4: Prior Technology Development Support**

The following questions request information about the funding and translational program support history for the technology to be developed under the proposed project. Please provide information about NIH and non-NIH support. Please also indicate whether the principal investigator and/or the technology have been supported by any NIH translational programs.

Confidential 4 Investigator: \_\_\_\_\_



35. Were any earlier translational or product development stages supported by any of the following NIH-sponsored translational programs? (select all that apply):
☐ NCAI (B-BIC, UC CAI, or NCAI-CC)
REACH 2015 (UofL ExCITE, MN-REACH, or LIBH)
REACH 2019 (KYNETIC, MBArC, ROI, CO-SPARK, or WE-REACH)
NIGMS STTR Tech Transfer Hubs (ASCEND, DRIVEN, SHARP Hub, Southeast Xlerator Network)
☐ tPPG
POCTRN (CAPCat)
☐ VITA
☐ CADET II
Excellence in Hemoglobinopathies
☐ Molecular Imaging of the Lung
☐ Thrombotic and Hemostatic Centers
Pulmonary Vascular-RV Axis
Preclinical GTRP
Preclinical PACT
Preclinical SMARTT
Transformative Platforms
☐ Bioengineering for HLBS
Large Animal Blood Disease Core
☐ None of the above
Other (Please provide name of NIH opportunity or program):